Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

Á¦¾àȸ»çºÐ¼® ½ÃÀåÁ¶»çº¸°í¼­

Á¦¾àȸ»çºÐ¼® ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.


»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 481 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Biomarker Partnering Terms and Agreements
»ùÇÃ
»óǰÄÚµå :229876
¹ÙÀÌ¿À ÀǾàǰ ¾÷°è¿¡¼­ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ °Å·¡ ±¸Á¶, ½ÇÁ¦ °Å·¡ »ç·Ê ¿¬±¸, 2007³â ÀÌÈÄÀÇ °Å·¡ µ¿ÇâÀ» Á¶»çÇßÀ¸¸ç, 550°³ ÀÌ»ó °è¾à ¹®¼­¿¡ ´ëÇÑ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,695
¹ßÇàÀÏ 2012³â 02¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö  
»ùÇÃ
»óǰÄÚµå :227852
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ M&A, ±âŸ °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ M&A °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à, ´ëÇü »ç¾÷ÀÚÀÇ M&A °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ, M&A °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 1000+ Pages
»ùÇÃ
»óǰÄÚµå :227851
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ M&A ¹× °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ M&A ¹× Á¦ÈÞ °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à, ´ëÇü »ç¾÷ÀÚÀÇ °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ µ¿Çâ, ÁÖ¿ä Á¦ÈÞ ¹× M&A °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,495
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 5000+ Pages
»ùÇÃ
»óǰÄÚµå :227850
ÀǾàǰ ¹× ÀÇ·á °ü·Ã »ç¾÷ÀÚÀÇ °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â¿¡ ü°áµÈ Á¦ÈÞ °è¾à °³¿ä(°Ç¼ö ¹× ±Ý¾× ±Ô¸ð), ´ëÇü °è¾à ¹× ´ëÇü »ç¾÷ÀÚÀÇ Á¦ÈÞ °è¾à »ó¼¼, »ê¾÷ ºÎ¹®, °è¾à À¯Çü, °³¹ß ´Ü°è, Ä¡·á ºÐ¾ßº° °¢Á¾ Á¦ÈÞ °è¾à µ¿Çâ, ÁÖ¿ä Á¦ÈÞ °è¾à µð·ºÅ丮 µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö 4000+ Pages
Best Practices: Translational Research - Positive Steps on the Path to Industry Transformation
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :227279
Áß°³¿¬±¸ÀÇ °³¿ä ¹× °úÁ¦, ÇöÀç ÁøÇàµÇ°í ÀÖ´Â Áß°³¿¬±¸ Ç÷§Æû ¹× º£½ºÆ® ÇÁ·¢Æ¼½º, ÁÖ¿ä ÀÌÇØ°ü°èÀÚ ´ë»ó Á¦¾ÈÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 4,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç IDC Health Insights
ÆäÀÌÁö¼ö Pages: 24
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011
»ùÇÃ
»óǰÄÚµå :227183
<h3>µµÇ¥</h3>
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 69
MSL Metrics: Measuring Success
»ùÇÃ
»óǰÄÚµå :226467
MSL ¿ªÇÒÀÇ ¹ßÀü°ú ¿¬±¸ÀÚ, º¸Çèȸ»ç, Á¤ºÎ¿ÍÀÇ °ü°è ºÐ¼®, KOL°úÀÇ °ü°è, MSL ºÐ¾ßÀÇ Æ¯¼öÈ­¿¡ ´ëÇÑ Âù¹Ý µîÀ» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 595
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç Doctor's Guide Publishing Limited (FirstWord Pharma)
ÆäÀÌÁö¼ö 26 Pages
European Pharmaceutical and Biotech Contract Manufacturing Markets
»ùÇÃ
»óǰÄÚµå :226599
À¯·´ÀÇ ÀǾàǰ ¹× ¹ÙÀÌ¿À ±â¼ú ¼öŹÁ¦Á¶(Pharmaceutical and Biotech Contract Manufacturing) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇϰí, ½ÃÀå ¹× ±â¼ú µ¿Çâ, ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ ¹®Á¦, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ, °æÀï ±¸µµ¿¡ ´ëÇØ Á¤¸®ÇßÀ¸¸ç, °íü Á¦Á¦, ¾×ü Á¦Á¦, ÁÖ»ç Á¦Á¦º° ÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå, Æ÷À¯·ù ¼¼Æ÷ ¹è¾ç ±â¹Ý ¹ÙÀÌ¿À ±â¼ú ¼öŹÁ¦Á¶ ½ÃÀå »ó¼¼ ºÐ¼®, À¯·´ ¹× ÁÖ¿ä ±¹°¡ÀÇ ¸ÅÃâ ¿¹Ãø, ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 6,000
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç Frost & Sullivan
ÆäÀÌÁö¼ö  
Novo Nordisk A/S: PharmaVitae Profile
»ùÇÃ
»óǰÄÚµå :229407
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Novo Nordisk A/SÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 80
CSL Limited: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229447
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ CSL LimitedÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 65
»ùÇÃ
»óǰÄÚµå :228159
¹Ì±¹, µ¿À¯·´, ¼­À¯·´, Áß±¹°ú Àεµ µîÀÇ ¾Æ½Ã¾Æ ¹× Áß³²¹ÌÀÇ ÀǾàǰ °³¹ß¼öʱâ°ü ½ÃÀåÀ» ºÐ¼®Çϰí, ÁÖ¿ä ±â¾÷ÀÇ °æÀï·ÂÀ» ±â¹ÝÀ¸·Î ÇÑ °³¿ä¿Í ºñ±³, 2016³â±îÁöÀÇ ½ÃÀå µ¿Çâ ¿¹Ãø µîÀÇ ÃֽŠÁ¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö Pages: 154
Pharmaceutical Digital Marketing and Social Media
»ùÇÃ
»óǰÄÚµå :223943
»ý¸í°úÇÐ ±â¾÷ÀÇ µðÁöÅÐ ¸¶ÄÉÆÃ(Digital Marketing) ¹× ¼Ò¼È ¹Ìµð¾î(Social Media) ÀÌ¿ëÀ» Á¶»ç ºÐ¼®Çϰí, »õ·Î¿î ¸¶ÄÉÆÃ ¹Ìµð¾î ±¸¼º, ¼Ò¼È ¹Ìµð¾î µµÀÔ µ¿Çâ, eMarketing ºÎ¹®ÀÇ ±¸¼º, ÀÎÀç, ¿¹»ê, ´ë¸®Á¡ ÀÌ¿ë µî¿¡ °üÇÑ ¾÷°è µ¿Çâ°ú Á¦¾È µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 187 Pages
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
»ùÇÃ
»óǰÄÚµå :222852
À¯·´ °¢±¹ÀÇ ÀÇ·áÁ¦µµ¿Í ¾à°¡°áÁ¤, »óȯ Á¦µµ¿¡ ´ëÇÑ °³¿ä¿Í °¢±¹ÀÇ µ¿Çâ ¹× ¹®Á¦Á¡, ¹ý±ÔÁ¦ µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 68
Research Report on Top 50 Companies of China's Pharmaceutical Industry, 2011-2012
»ùÇÃ
»óǰÄÚµå :224494
Áß±¹ Á¦¾à »ê¾÷ÀÇ ´ë±â¾÷ 50»ç¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ±â¾÷ °³¿ä, »ç¾÷ ¿î¿µ, ¹ßÀü Àü·« µî¿¡ ´ëÇØ ºÐ¼® ¹× Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,800
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç China Research and Intelligence
ÆäÀÌÁö¼ö Pages: 65
Pharma Product Launches: Strategies for Success
»ùÇÃ
»óǰÄÚµå :222809
ó¹æ¾à ½ÃÀåÀÇ È¯°æ°ú ÇâÈÄ Á¦Ç° Ãâ½Ã µ¿Çâ, Ãâ½Ã Àü·«À» È¿°úÀûÀÎ ½ÃÇà°ú °èȹ, Á¦Ç° Â÷º°È­ÀÇ Á߿伺¿¡ ´ëÇØ ³íÀÇÇßÀ¸¸ç, Á¦Ç° Ãâ½Ã¿¡ °üÇÑ »ç·Ê ¿¬±¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 595
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Doctor's Guide Publishing Limited (FirstWord Pharma)
ÆäÀÌÁö¼ö 30 Pages
Payer Agreements: Splitting the Risk
»ùÇÃ
»óǰÄÚµå :219289
º¸ÇèÀÚ ½ºÅ´(Payer Schemes)¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ±¹°¡º° µ¿Çâ, ¼º°ø ºñ°á µîÀ» ÃֽŠ»ç·Ê ¿¬±¸¿Í ÇÔ²² ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 695
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Doctor's Guide Publishing Limited (FirstWord Pharma)
ÆäÀÌÁö¼ö 41 Pages
Merck KGaA: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229422
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Merck KGaAÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 70
Gilead Sciences Inc.: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229421
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Gilead Sciences Inc.ÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫 ½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â°£), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 71
Actelion Ltd: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229420
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Actelion LtdÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 56
Strategies for Effective Partnerships Between Pharmaceutical and Diagnostic Companies
»ùÇÃ
»óǰÄÚµå :228145
ÀǾàǰ ¹× Áø´Ü(Pharmaceutical and Diagnostic) ±â¼úÀÇ ´Ù¸¥ ¾÷Á¾ ±â¾÷°£¿¡ ä¿ëµÇ°í ÀÖ´Â ´Ù¾çÇÑ Á¦ÈÞ ¸ðµ¨¿¡ °üÇÑ »ç·Ê ¿¬±¸¸¦ ÅëÇÏ¿© ¸®½ºÅ©¿Í º¸»óÀ» ºÐ¼®Çϰí, Çù·Â °ü°è¿¡ µé¾î°£ ±â¾÷ÀÌ Á÷¸éÇÑ ¹®Á¦¿Í ÆÄÆ®³Ê ¼±Á¤½Ã °¨¾ÈÇØ¾ß ÇÒ ¿äÀÎ, Á¦ÈÞ °è¾àÀÇ º£½ºÆ® ÇÁ·¢Æ¼½º¿¡ ´ëÇÑ Á¦¾ÈÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö Pages: 100
Otsuka Pharmaceutical Co., Ltd: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229419
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Otsuka Pharmaceutical Co., LtdÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â), ±â¾÷ °³¿ä, »ç¾÷ Àü·« µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 63
Human Genome Sciences, Inc.: PharmaVitae Report
»ùÇÃ
»óǰÄÚµå :229413
ÀǾàǰ ¾÷°è¿¡¼­ÀÇ Human Genome Sciences, Inc.ÀÇ ÇöÀç ¹× ÇâÈÄ ½ÇÀû µ¿Çâ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÁÖ¿ä Á¦Ç° °³¹ß ¹× ÆÇ¸Å µ¿Çâ, À繫 ½ÇÀû ¹× ¿¹Ãø(ÃÑ 6°³³â°£), ±â¾÷ °ü°è¿Í °æÀï·Â µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 5,700
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 31
Health Outcomes Liaisons: Managing a Field-Based Team that Speaks the Payer's Language
»ùÇÃ
»óǰÄÚµå :219123
ÀÇ·áºñ »ó½Â°ú °æÀï ½ÉÈ­·Î »ý¸í°úÇÐ ±â¾÷Àº ºê·£µå ÀǾàǰ°ú Á¦³×¸¯ ÀǾàǰÀ» ºÒ¹®ÇÏ°í °øÁ¤ÇÑ ºñ¿ë°ú Á¦Ç° °¡Ä¡ Áõ¸í¿¡ ²÷ÀÓ¾øÀÌ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. º¸ÇèÀÚ¿Í Ä¿¹Â´ÏÄÉÀ̼ÇÀ» ÃëÇÏ¿© ÃÖ¼±ÀÇ »óȯÀ» È®º¸Çϱâ À§Çؼ­, ±â¾÷Àº °¢°¢ HOL(Health Outcomes Liaisons)À» ¹èÄ¡Çϰí ÀÖ½À´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 7,695
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Cutting Edge Information
ÆäÀÌÁö¼ö 128 Pages
Vaccine Partnering Terms and Agreements
»ùÇÃ
»óǰÄÚµå :217633
¹é½Å(Vaccine) °³¹ß¿¡ °üÇÑ ´ë±â¾÷ÀÇ Á¦ÈÞ °è¾à µ¿ÇâÀ» Á¶»ç ºÐ¼®Çϰí, °è¾à Á¶°Ç, °è¾à ±¸Á¶, °è¾à ¹®¼­, Æò±Õ °è¾à ±Ý¾× µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,695
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Current Partnering, a division of Wildwood Ventures Limited
ÆäÀÌÁö¼ö Pages: 663
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
»ùÇÃ
»óǰÄÚµå :216726
¾Ï, °¨¿°º´, ÆÐÇ÷Áõ, ¾Ë·¹¸£±âÀÇ Ä¡·á¿Í ¿¹¹æÀ» À§ÇØ ÅçÀ¯»ç¼ö¿ëü(TLR : Toll-Like Receptor)¸¦ Ç¥ÀûÀ¸·Î ÇÑ ¼ÒºÐÀÚ, ´Ü¹éÁú, DNA, RNA, ¹é½Å °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ´ëÇØ ºÐ¼®Çϰí, ÀÛ¿ëÁ¦ ¹× ±æÇ×Á¦, Ç׿øº¸°­Á¦(Adjuvant) ¹× ¹é½Å ¿¬±¸°³¹ß ÇöȲ°ú ÇâÈÄ ¿¹ÃøÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 800
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç La Merie Publishing
ÆäÀÌÁö¼ö 152 Pages